BSE - Delayed Quote • INR Suven Life Sciences Limited (SUVEN.BO) Follow Compare 121.55 -0.65 (-0.53%) At close: January 24 at 3:29:45 PM GMT+5:30 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Suven doses first subjects in trial of SUVN-I6107 for cognitive disorders SUVN-I6107 is a muscarinic M1 positive allosteric modulator intended for treating cognitive disorders. Performance Overview Trailing total returns as of 1/24/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX Return SUVEN.BO S&P BSE SENSEX YTD -3.99% -2.63% 1-Year +11.65% +8.27% 3-Year +31.83% +29.06%